生产企业：Revolution Medicines
Daraxonrasib (RMC-6236) is an investigational targeted therapy that nearly doubled survival in a Phase 3 clinical trial for metastatic pancreatic cancer, increasing median survival from 6.7 months to 13.2 months and reducing the risk of death by 60%.
Daraxonrasib (RMC-6236) is an investigational targeted therapy that nearly doubled survival in a Phase 3 clinical trial for metastatic pancreatic cancer, increasing median survival from 6.7 months to 13.2 months and reducing the risk of death by 60%.
Oral, direct RAS(ON) multi-selective (pan-RAS) small-molecule inhibitor: targets GTP-bound (active) mutant and wild-type RAS, blocking active-state RAS signaling across a broad range of cancers driven by oncogenic RAS.
Treatment of adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or are not candidates for multiagent systemic therapy
共 1 项相关疾病
每项发明一条，涵盖美国、欧洲、PCT 与中国的同族专利。
